[7] In June 2018, IACM took part in the open session of the World Health Organization's Expert Committee on Drug Dependence meeting related to medical cannabis[8][9] and joined an official civil society statement[10] in December 2020 to the United Nations Commission on Narcotic Drugs which resulted in the change of international scheduling of cannabis.
[11][12][13][14] During the COVID-19 pandemic, the Board of IACM issued a statement saying that "there is no evidence that individual cannabinoids [...] or cannabis preparations protect against infection with the SARS-CoV2 virus or could be used to treat COVID-19"[15][16] while mentioning that the IACM-Bulletin reported on several occasions on laboratory studies suggesting that cannabinoids may have antiviral or antibacterial effects.
[17] Between 2001 and 2004, IACM edited[18] the scholarly Journal of Cannabis Therapeutics[19][20] published by Haworth Press.
IACM only conducted one own clinical study: a cross-sectional survey completed by 953 participants from 31 countries about their methods of administration of medical cannabis.
The association gives the IACM Awards to "outstanding clinicians and scientists for their major contributions to cannabinoid research and/or to the re-introduction of cannabis into modern medicine.